UBS Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Negative 60.8%

Neg 60.8% Neu 0% Pos 0%

UBS analyst Ashwani Verma downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Neutral and raises the price target from $55 to $85.